Effects of canagliflozin on body weight and relationship to HbA(1c) and blood pressure changes in patients with type 2 diabetes

AIMS/HYPOTHESIS: Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces HbA(1c), body weight and systolic BP (SBP) in patients with type 2 diabetes. As weight loss is known to reduce both HbA(1c) and SBP, these analyses were performed to evaluate the contribution of weight loss resultin...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Diabetologia
Главные авторы: Cefalu, William T., Stenlöf, Kaj, Leiter, Lawrence A., Wilding, John P. H., Blonde, Lawrence, Polidori, David, Xie, John, Sullivan, Daniel, Usiskin, Keith, Canovatchel, William, Meininger, Gary
Формат: Artigo
Язык:Inglês
Опубликовано: 2015
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800739/
https://ncbi.nlm.nih.gov/pubmed/25813214
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00125-015-3547-2
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы